Fed. Circ. Says J&J Unit's HIV Treatment May Enter Duty-Free

Law360 (April 27, 2021, 3:02 PM EDT) -- The Federal Circuit has upheld a Johnson & Johnson unit's $100 million victory at the federal trade court, saying in a decision publicly released Monday the company could import its HIV treatment Prezista into the U.S. duty-free.

The three-judge panel found that darunavir ethanolate, the active ingredient in Janssen Ortho LLC's Prezista, is covered in Table 1 of the Pharmaceutical Appendix of the U.S. Tariff Schedule, which lists drugs that may enter the U.S. duty free.

The federal government had stressed that the table listed darunavir but not its ethanolate suffix, thus requiring Janssen to pay a 6.5% tariff on the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!